Longevity Health Q2 FY26 net loss narrows 0% to $1,883,290; net sales fall 21% to $395,991
XAGE•Q2 and six-month results
Longevity Health Holdings posted a GAAP net loss of $3.32 million for the six months ended June 30, 2026, narrowing 2%.
Net sales fell 22% to $787,755, reflecting lower demand tied to increased competition in the bio-aesthetics market.
Operating loss narrowed 39% to $2.05 million as total operating expenses dropped 36% to $2.53 million.
Other expense, cash, and going concern
Other expense widened to $1.26 million, driven by a $1.17 million increase in the contingent liability for the Puritan Settlement.
Cash was $35,471 at June 30, 2026. Management flagged substantial doubt about going concern and expects to seek additional financing.
